Recombinant antibody production leverages Chinese hamster ovary (CHO) cells due to their adaptability in expressing complex biologics. Improving these processes involves adjusting various variables, including cell line development, media composition, and bioreactor settings. A key goal is to maximize antibody titer while lowering production financi